Wells Fargo & Company Begins Coverage on Merus (NASDAQ:MRUS)

Investment analysts at Wells Fargo & Company assumed coverage on shares of Merus (NASDAQ:MRUS) in a research note issued to investors on Friday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $91.00 price target on the biotechnology company’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 119.07% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Citigroup increased their price objective on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. HC Wainwright reissued a “buy” rating and issued a $85.00 price objective on shares of Merus in a report on Monday, December 2nd. Guggenheim reissued a “buy” rating and issued a $109.00 price objective (down from $111.00) on shares of Merus in a report on Tuesday, December 3rd. The Goldman Sachs Group began coverage on Merus in a report on Thursday, November 21st. They issued a “buy” rating and a $73.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $85.00 price objective on shares of Merus in a report on Monday, December 9th. One analyst has rated the stock with a sell rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $86.08.

Merus Trading Down 0.3 %

NASDAQ:MRUS opened at $41.54 on Friday. The firm has a market capitalization of $2.84 billion, a PE ratio of -10.52 and a beta of 1.11. The stock has a 50 day moving average of $42.24 and a 200-day moving average of $47.86. Merus has a 52 week low of $35.67 and a 52 week high of $61.61.

Institutional Investors Weigh In On Merus

A number of institutional investors and hedge funds have recently modified their holdings of MRUS. Avior Wealth Management LLC acquired a new stake in shares of Merus during the 4th quarter valued at $76,000. nVerses Capital LLC lifted its position in shares of Merus by 750.0% during the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,500 shares during the last quarter. US Bancorp DE acquired a new stake in shares of Merus during the 3rd quarter valued at $103,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Merus by 24.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 489 shares during the last quarter. Finally, MML Investors Services LLC acquired a new stake in shares of Merus during the 3rd quarter valued at $206,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.